Kodiak Sciences News Today

PALO ALTO, Calif., May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a...

Shares of Kodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) have received a consensus recommendation of “Reduce” from the seven analysts that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the […]

Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile.KSI-501 clinical and non-clinical data...

Acuitas Investments LLC lifted its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD – Free Report) by 59.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 234,092 shares of the company’s stock after purchasing an additional 87,043 shares during the period. Acuitas […]

/PRNewswire/ -- DelveInsights Dry Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment...

/PRNewswire/ -- DelveInsights Corneal Edema Market Insights report includes a comprehensive understanding of current treatment practices, corneal edema...

Kodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) has received a consensus recommendation of “Reduce” from the seven research firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The […]

Shares of Kodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) have been given an average rating of “Reduce” by the seven ratings firms that are covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the […]

Kodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) has earned a consensus rating of “Reduce” from the seven analysts that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and one has issued a buy recommendation on the company. The […]

Kodiak Sciences Inc. misses on earnings expectations. Reported EPS is $-1.13 EPS, expectations were $-0.86. Kodiak Sciences Inc.